Bioventus Inc. Class A Common Stock (BVS)

FairStock Score: 52/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Bioventus as a medical-device turnaround. The filed record is improving: in fiscal Q2 2026, the quarter ended 2026-06-27, revenue was $153.2M, net income $33.4M, and diluted EPS $0.47. A year earlier, in fiscal Q2 2025, the quarter ended 2025-06-28, revenue was $147.7M, net income $7.5M, and EPS $0.11. For fiscal year 2025, the year ended 2025-12-31, revenue was $568.1M and net income $22.7M, versus fiscal year 2024, the year ended 2024-12-31, revenue of $573.3M and net loss of $36.1M. So earnings are swinging up, though revenue is not compounding quickly. Free cash flow is $94.3M trailing, a 9.8% FCF yield on the $960.6M market cap, which is the most Graham-like attraction. However, FairStock's price-based measures at the 2026-10-13 close of $13.56 show P/E 17.38, P/B 4.05, Graham Number $7.67, and margin of safety -76.79%. The balance sheet gives me pause: debt-to-equity 0.95, Altman Z-Score 1.34, ROCE 5.49%. Piotroski 7/9 and ROE 25.68% are positives, but high ROE with modest ROCE can reflect leverage or accounting. The Lynch category is TURNAROUND, returned to profit after a loss within last three years. Without evidence of durable pricing power or a wide moat, I'd treat this as a speculative recovery, not a classic bargain. The latest quarter needs to become the norm, not a spike.

In plain English: Bioventus makes medical products that treat pain and muscle and bone problems. The business has gone from losses to profits, and the latest quarter showed more revenue and much more net income than a year earlier. At $13.56 on 2026-10-13, the shares look expensive compared with the company's accounting value and a conservative value check, even though cash generation is solid.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-27) · fiscal Q1 2026 10-Q (period ended 2026-03-28) · fiscal Q3 2025 10-Q (period ended 2025-09-27) · fiscal Q2 2025 10-Q (period ended 2025-06-28) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer